Holding(s) in Company

RENOVO GROUP PLC (“the Company”) 26 October 2006 Holding in Company The Company has received notification from Fidelity International on the dates indicated below that the legal entities listed b

RENOVO GROUP PLC (“the Company”) 26 October 2006 Holding in Company The Company has received notification from Fidelity International on the dates indicated below that the legal entities listed below are interested in ordinary shares of 10p each of the Company’s issued share capital in the amounts listed below.

Date of Notification Date Company received Notification FMR Corp. and its direct and indirect subsidiaries FIL and its direct and indirect subsidiaries TOTAL Number of ordinary shares TOTAL Ownership Percentage
25 October 2006 26 October 2006 12,698,363 10,592,908 23,291,271 13.15%
Change in Holding since last notification +279,453 - -

Contacts Goldman Sachs - Howard Rowe 0207 774 1000 Nomura Code – Chris Collins 0207 776 1207 Buchanan Communications - Tim Anderson 07710 328 560 Renovo Group plc – Simon Bielecki 0161 606 7332 END

Holding in Company

RENOVO GROUP PLC (“the Company”) 2nd November 2006 Holding in Company The Company has received notification from the Goldman Sachs Group, Inc.

RENOVO GROUP PLC (“the Company”) 2nd November 2006 Holding in Company The Company has received notification from the Goldman Sachs Group, Inc. (GS Inc) on the date indicated below that the legal entities listed below are interested, by attribution only,in ordinary shares of 10p each of the Company’s issued share capital in the amounts listed below.

Date of Notification Date Company received Notification Goldman, Sachs & Co., a wholly owned subsidiary of GS Inc Goldman Sachs International, a wholly owned subsidiary of GS Inc TOTAL Number of ordinary shares held by Goldman Sachs Inc TOTAL Ownership Percentage
1 November 2006 2 November 2006 17,270,476 2,810,761 6,170,347 11.3%
Change from last notification - - -

Contacts Goldman Sachs - Howard Rowe 0207 774 1000 Renovo Group plc – Robin Cridland 0161 606 7332

Holding(s) in Company

RENOVO GROUP PLC (“the Company”) 6th November 2006 Holding in Company The Company has received notification from JP Morgan Partners, LLC ("JPMP")of 1221 Avenue of the Americas, New York, NY, Un

RENOVO GROUP PLC (“the Company”) 6th November 2006 Holding in Company The Company has received notification from JP Morgan Partners, LLC ("JPMP")of 1221 Avenue of the Americas, New York, NY, United States that JPMP has decreased its material interest in the share capital of Renovo Group plc to 6%. Details are as follows: Number of shares sold: 5,322,947 (3.0%) Total number of shares held by JP Morgan Partners, LLC: 10,645,894 (6.00%). Contacts

Holding(s) in Company

RENOVO GROUP PLC (“the Company”) 7 November 2006 Holding in Company The Company has received notification from Atlas Venture on the date indicated below that the legal entities listed below are i

RENOVO GROUP PLC (“the Company”) 7 November 2006 Holding in Company The Company has received notification from Atlas Venture on the date indicated below that the legal entities listed below are interested in ordinary shares of 10p each of the Company’s issued share capital in the amounts listed below.

Date of Notification Atlas Venture Fund V, L.P. Atlas Venture Fund V-A, C.V. Atlas Venture Fund V-A, L.P. TOTAL Number of ordinary shares TOTAL Ownership Percentage
6 November 2006 17,940,689 4,457,581 298,137 22,696,407 12.8%
Change in Holding since last notification -4,330,093 -1,075,864 -71,957

For further information please contact Renovo Group plc – Simon Bielecki, Head of Communications 0161 606 7328

Notification of Preliminary Results

RENOVO GROUP PLC PRELIMINARY RESULTS NOTIFICATION Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the prevention and reduction of scarring at mult

RENOVO GROUP PLC PRELIMINARY RESULTS NOTIFICATION Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the prevention and reduction of scarring at multiple body sites, will announce its preliminary results for the year ending 30 September 2006 on Thursday 14 December 2006. Professor Mark Ferguson, CEO, and Rob Cridland, Executive Director, Finance and Business Development & Company Secretary, will host a briefing for analysts at 09:30am on Thursday 14 December 2006 followed by a press briefing at 11:00am at the offices of Buchanan Communications, 45 Moorfields, London, EC2Y 9AE. Simultaneous to the meeting at 09:30am, there will be a live audio web cast of the preliminary results presentation. To connect to the web cast facility, please go to the Company’s website www.renovo.com approximately 5 minutes (09:25 am) before the start of the briefing. For further information please contact: Renovo Group plc Professor Mark Ferguson, Chief Executive Officer +44 (0) 161 606 7222 Simon Bielecki, Head of Communications +44 (0) 161 606 7328 Buchanan Communications Tim Anderson/Lisa Baderoon/Mary-Jane Johnson +44 (0) 20 7466 5000

Technology Pioneer 2007

RENOVO SELECTED BY THE WORLD ECONOMIC FORUM AS A TECHNOLOGY PIONEER FOR 2007 Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the prevention and red

RENOVO SELECTED BY THE WORLD ECONOMIC FORUM AS A TECHNOLOGY PIONEER FOR 2007 Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the prevention and reduction of scarring at multiple body sites, is pleased to announce that it has been selected by the World Economic Forum as one of the Technology Pioneers for 2007. The Company is initially focused on developing drugs for the prevention and reduction of scarring in the skin. Renovo will then look to extend its drug candidates to other body sites, such as the eye, tendons and nerves. Renovo receives this award having been recognised as developing and applying innovative technologies in the areas of biotechnology and health. This year’s class of companies were selected not only because of the cutting-edge work, but also because their work has potential long-term impact on business and society. The final selection of the 47 Technology Pioneers was made by a panel of world leading technology and venture capital experts appointed by the World Economic Forum. The winners were selected from a group of 225 nominees. Commenting on the award, Professor Mark W J Ferguson, Chief Executive Officer of Renovo, said: “We are delighted to be recognised by the World Economic Forum as a Technology Pioneer and believe that this endorsement will serve to boost our profile and reputation across the world as an innovative company developing first-in-class drugs. I look forward to participating in the World Economic Forum meeting in Davos next January.” Peter Torreele, Managing Director of the World Economic Forum. said: “The competition to become a Technology Pioneer has been more intense than ever. It is evident that technology and innovation is playing a key role in the shifting power equation at a global level. Driving this shift is the tremendous amount of innovation taking place outside of traditional hubs. The wide geographic spread of this year’s Technology Pioneers is a testament to this trend. We are pleased to welcome these exciting companies to our Community of Technology Pioneers, and look forward to engaging these industry leaders of the future into the community of the World Economic Forum.” For further information please contact: Renovo Group plc Professor Mark Ferguson, Chief Executive Officer +44 (0) 161 606 7222 Simon Bielecki, Head of Communications +44 (0) 161 606 7328 Buchanan Communications Tim Anderson/Lisa Baderoon/Mary-Jane Johnson +44 (0) 20 7466 5000 About Renovo Group plc Renovo is a biopharmaceutical product company and is the world leader in scar prevention and reduction research, and the development of drugs to prevent and reduce scarring. The Company has a highly skilled management team with over 30 years of research in the field of scarring, and significant pharmaceutical industry experience. Renovo has a portfolio of drugs which exploit different novel mechanisms of action to prevent and reduce scarring at multiple body sites and to accelerate healing. The Company’s deep pipeline includes four drugs in phase II clinical development, a further four advanced pre-clinical candidates and nine other pre-clinical candidates. Scarring can result from acute injury in, or surgery to, the skin, blood vessels, eyes, nerves, internal organs, tendons and ligaments. These are high value markets of significant unmet medical need. Renovo aims to be first to market with a pharmaceutical drug in the US and Europe to prevent and reduce scarring. Current demand is inadequately met and there is no near term competition. According to external research conducted by The Mattson Jack Group, the potential commercial market for prevention and reduction of scarring in the skin is worth in the order of US$4 billion per annum in the US alone. About the World Economic Forum The World Economic Forum (http://www.weforum.org), based in Geneva, Switzerland, is an independent organization committed to improving the state of the world. Funded by the contributions of 1,000 of the world's foremost corporations, the Forum acts in the spirit of entrepreneurship in the global public interest to further economic growth and social progress. The Forum serves its members and society by creating partnerships between and among business, political, intellectual and other leaders of society to define, discuss and advance key issues on the global agenda. Incorporated in 1971 as a foundation, the World Economic Forum is impartial and not-for-profit, and is tied to no political, partisan or national interests. In 1995 the Forum was awarded NGO consultative status with the Economic and Social Council of the United Nations. About the Technology Pioneers To be selected as a Technology Pioneer, a company must be involved in the development of life-changing technology innovation and have the potential for long-term impact on business and society. In addition, it must demonstrate visionary leadership, show all the signs of being a long-standing market leader – and its technology must be proven. Previous Technology Pioneers have included Autonomy, Cambridge Silicon Radio, Encore Software, Google, Millennium Pharmaceuticals and Napster. The pioneering companies’ products include microscopic pill cameras, bio sensors that localize landmines, implantable medical devices for the treatment of brain tumours, mobile television service, anti-scarring drugs, open source webrowsers, video headsets, thin-film diamond coatings, solar air-conditioner equipment, paper batteries for music-playing greeting cards, and even an automatic and compacting trash bin powered by solar energy. The selection criteria include: 1) Innovation. The company’s technology must be truly innovative. A new version or repackaging of an already well-accepted technological solution does not qualify as an innovation. The innovation should be recent – not more than two years old. The company should invest significantly in R&D. 2) Potential Impact. This company’s technology must have the potential to have a substantial long-term impact on business and society in the future. 3) Growth and Sustainability. The company should have all the signs of being a long-term market leader and should have well-formulated plans for future development and growth. 4) Proof of Concept. The company must have a product on the market or have proven practical applications of the technology. Companies in “stealth” mode and companies with untested ideas or models will not qualify. 5) Leadership. The company must have visionary leadership that plays a critical role in driving the company towards reaching its goals. 6) Status. The company must not currently be a Member of the World Economic Forum. This criterion applies to the parent company – thus wholly-owned subsidiaries of large firms are not eligible. Go to www.weforum.org/techpioneers/2007 for the entire list of Technology Pioneers and interviews with the CEOs of the selected companies. For more specific information, please e-mail: tech.pioneers@weforum.org Download print-quality high resolution photographs of the CEOs of the selected companies at: www.pbase.com/forumweb/techpioneers2007

Holding(s) in Company

RENOVO GROUP PLC (“the Company”) Holding in Company The Company has received notification that, as at close of business on 7 December 2006, the Goldman Sachs Group, Inc.

RENOVO GROUP PLC (“the Company”) Holding in Company The Company has received notification that, as at close of business on 7 December 2006, the Goldman Sachs Group, Inc. (GS Inc) was interested, by attribution only, in 5,552,775 Renovo ordinary shares. Of these 5,552,775 shares: • The interest in 1,307,335 shares arose from the interest held by Goldman Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as a custodian for its customers. • The interest in 4,245,440 shares arose from a beneficial interest held by Goldman Sachs International, a wholly-owned indirect subsidiary of GS Inc. Contact Renovo Group plc – Simon Bielecki 0161 606 7328

Holding(s) in Company

RENOVO GROUP PLC (“the Company”) 19 December 2006 Holding in Company The Company has received notification from HealthCap IV GP SA on the date indicated below that the legal entities listed below

RENOVO GROUP PLC (“the Company”) 19 December 2006 Holding in Company The Company has received notification from HealthCap IV GP SA on the date indicated below that the legal entities listed below are interested in ordinary shares of 10p each of the Company’s issued share capital in the amounts listed below.

Date of Notification HealthCap IV Bis, L.P. HealthCap IV, L.P. HealthCap IV IV, KB OFCO Club IV TOTAL Number of ordinary shares TOTAL Ownership Percentage
19 December 2006 8,099,875 11,209,516 817,987 306,631 20,434,009 11.53%
Change in Holding since last notification -839,260 -1,161,463 -84,755 -31,771 -2,117,249

For further information please contact Renovo Group plc – Simon Bielecki, Head of Communications 0161 606 7328

2006 Annual Report

RENOVO GROUP PLC Copies of the 2006 Annual Report, notice of Annual General Meeting and proxy form have been submitted and will shortly be available for inspection at the UK Listing Authority's do

RENOVO GROUP PLC Copies of the 2006 Annual Report, notice of Annual General Meeting and proxy form have been submitted and will shortly be available for inspection at the UK Listing Authority's document viewing facility situated at the Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS. For further information please contact: Simon Bielecki, Head of Communications +44 (0) 161 606 7328

Holding(s) in Company

RENOVO GROUP PLC (“the Company”) 22 January 2007 Holding in Company The Company has received notification from HealthCap IV GP SA on the date indicated below that the legal entities listed below

RENOVO GROUP PLC (“the Company”) 22 January 2007 Holding in Company The Company has received notification from HealthCap IV GP SA on the date indicated below that the legal entities listed below are interested in ordinary shares of 10p each of the Company’s issued share capital in the amounts listed below.

Date of Notification HealthCap IV Bis, L.P. HealthCap IV, L.P. HealthCap IV IV, KB OFCO Club IV TOTAL Number of ordinary shares TOTAL Ownership Percentage
22 January 2007 7,657,621 10,597,474 773,325 289,889 19,318,309 10.90%
Change in Holding since last notification -79,278 -109,715 -8,006 -3,001 -200,000

For further information please contact Renovo Group plc – Simon Bielecki, Head of Communications 0161 606 7328

Syndicate content